- Home
- GITS vs AIDX Comparison
GITS vs AIDX Comparison
Compare GITS & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | AIDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | South Korea | United States |
| Employees | 5 | 14 |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | AIDX |
|---|---|---|
| Price | $2.02 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 937.7K | 331.9K |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.51 |
| 52 Week High | $7.09 | $14.09 |
Technical Indicators
Market Signals| Indicator | GITS | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 31.74 |
| Support Level | $1.45 | N/A |
| Resistance Level | $2.26 | $0.70 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 36.27 | 4.48 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.